Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like Thermodox is superior to Doxil in terms of safety profile...
Doxil is doxorubicin encapsulated in a liposome coated with methoxypolyethylene glycol, a type of rubber. The
drug leaks out of the liposome slowly. The coating keeps over 90% of the doxorubicin inside the liposome while
the liposome travels in the blood, thus getting more of the active agent to the tumor than non-encapsulated
doxorubicin. However, that still means up to 10% of the Doxil may leak out before reaching the tumor and affect
healthy tissue.
Patients typically receive treatments once every four weeks. Doxil is given by intravenous infusion, normally in
the doctor’s office or in a clinic.
ThermoDox works by keeping more of the doxorubicin in its patented liposome after intravenous administration
until heat – which may be applied by radiofrequency ablation (RFA), microwave thermotherapy, high-frequency
ultrasound or other methods – releases it. By targeting a cancerous tumor with heat, the doxorubicin can be
directed precisely to the tumor.
I am optimistic due to the inherent technology. Delivery of highly potent drug without impacting healthy tissues and directly into the tumor is closer to the holy grail than any I have seen.
Your posts are either wary or being careful etc..are you waiting to get in at lower prices ? CLSN train has left the station...
Some very good funds are in big time..expecting to be $10 stock by end of this year...
Ayer Capital has good track record.
Manny,
I know about Ayer Capital very well for personal reasons. They are very smart folks and I have literally bet my farm when I saw they bought 1.25 millon shares for $4 millon. That's about 3.20 pps or so.
They usually hold for a significant news or development.
Anything below 3 is a great opportunity.
I was watching L2 as well. Did not notice any big blocks going into close.
I strongly suspect pps will run 15+ by mid next week
$20 Target !!
Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Model Revisions Ahead of DIFICID Launch
Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $20.
That's what I have pounding on the table. Low 20's is my target.
Can you then please explain how you arrived at $15ish target ? Is that because you got closer to $12+ and a 3 point jump isn't too bad ?
I know the history of VPHM that traded in low 20's purely because of their monopoly on branded Vancomycin which by the way was their only drug that they brought the license for. Vanco was the last standard treatment but still not effective from stopping the relapse that Fido will do as much as 54%. Hospitals will realize this soon...
I am expecting to be close to $20 as the revenue potential unfolds upon approval
I agree. OPTR could surpass $15 before the PDUFA date. 25 people of new recruits speaks of some big plans brewing within OPTR
I seriiously expect pps to be close to $20 early June after approval is granted. The potential to kill c-diff with far less relapse rates compared to current standard care is big.
From the PR today, looks like OPTR's drug DIFICID will eat Vancomycin's lunch !!
http://finance.yahoo.com/news/Data-Presented-at-Digestive-prnews-4057287648.html?x=0&.v=1
This stock has $20 written all over it. The findings from the journal adds more to the case that Difimicin will eat into Vanco's market share quickly. Treatment of C-Diff is a huge market and why would anyone prescribe vancomycin when Difimicin is so effective on cutting down the relapse rates as much as 45% ?
I added to my position as well. I am expecting pps to approach 15 prior to PDUFA date and 17 or so post approval.
I see OPTR at 17+ range upon approval easily. C diff is a serious issue and OPTR drug prevents relapse which is key differentiator from VPHM's vanco. I see OPTR's drug grabbing Vanco's market share rapidly...
Agree...expect to be 15+ around that date with 18+ upon approval. Panel vote has been very positive..
I bought more (adding to my core holdings). Expecting renewed surge going into end of May with 15+ prior to PDUFA date. Post approval expecting 18+ range easily. Remember their drug avoids relapses which is going to beat vanco in getting market share.
with overwhelming panel vote, approval is almost certain. I expct OPTR to climb to 15+ range and upon approval into 18+. 6 months target is 20+
You think INO will reach $10 in a years time ? Seems its vaccine delivery technology is unique and higly effective. If their HIV vaccine alone turns positive in Phase I (?), we will be off to the race..
I bought another chunk of INO at 1.17 today. The Phase I results alone would propel this stock to 5+ minimum.
generic modafinil ?
I think PLX took the minimalist approach of providing what's required (must to have) for NDA and not 'nice to have'. Adding more data when not strictly required can cut both ways. Regardless the fact PDUFA date can get extended, as a management would you truly want this delay ? FDA just used their perogative to ask anything & everything...would be a shame on them when this is approved elsehwere in the world earlier than in US.
It will. Be patient, my friend...
Bottom line...no big funds or institutions are buying the MNTA story anymore...Oppenheimer did initially for reasons that somehow rest of the big boys are not agreeing...
The street won't touch as long as MNTA earnings momentum continue to be at jeopardy.
The fact that the presentation will be oral and not a poster, is a great sign. Usually Oral presentations are reserved for important findings. So expect to hear very positive news on the saftey for sure. WIth regard to efficacy, we have to see but I am hopeful.
It's matter of time this gets to $3 level...funds are loading up
Plan to get 100K shares and tuck it away in a separate Ameritrade account for a year. I know one particular hedge fund that has invested big on INO based on their unique technology and its fund manager is top notch.
Where do you see the pps of INO a year from now ? TIA
US has tons of Natural Gas reserves that will last for next 100 years. I see this as a good riddence of oil dependency albeit painful short term if it goes up that much...
Just load more if you see any weakness which I doubt. This is a $10 stock at minimum. I expect DEPO to steadily climb to $15 range in couple of months
DEPO may be halted tomorrow afternoon...news after the market likely...
A note from FDA on the subject a material information whether positive or negative. It's does move the PPS as we have seen for both TEVA and MNTA. TEVA did the right thing on the disclosure
I hope so but what's Minor Deficiency Letter ? Doesn't look like TEVA's T-nox will never get approved contrary to all the assumptions. Their approval getting to closer to becoming a reality.
I really will be surprised if they (TEVA) were to twist thier PR by saying something significant (if communicated as such from FDA) as 'minor'
MNTA will be hit hard...
I don't think ABT knows either way of DM-1796 getting approved or not. If they knew (somehow) it will not get approved, they would have waited until FDA decision to get out clean.
It's likely that ABT made the decision based on DM-1796's portfolio value. Simple cost of marketing vs ROI. For a big pharma like ABT, while the cost of marketing may not be that high, ROI may not be sufficient enough to warrant continued interest.
Regardless, DEPO would be a winner. ABT will pay their financial obligations per contract and DEPO can still partner with other pharma. I don't think DEPO can force ABT to launch, IMO
It still would be controversial if not illegal to set that target of $15 for non-subscribing general public while internally they (GS) had circulated note to their investors otherwise - written or verbal. It all in the end amounts to 'real' info always has a price tag.
All in all, I rather would stick to your DD & be thankful for it than GS which largely is a BS organization that they have become.
XOMA is a scam. ATM is indeed a apt name that turned out to be a cookie jar for them at shareholders expense
GS report says overhang would exist until FDA rejects others ANDA.
If FDA has not rejected TEVa's or others ANDA yet, what are the chances they will reject soon ? Wish they have some definitive timeline like PDUFA.